Yield Hunters Fuel a $331 Billion Wave of Emerging Bond Sales
Strong demand from yield-hungry investors is driving a surge in developing-world bond sales as borrowers race to secure financing ahead of any further wobbles in global markets.
Since the beginning of the year, emerging-market governments and companies have sold $331 billion in debt denominated in hard currencies like the dollar and euro, according to data compiled by Bloomberg. That is the fastest pace in four years and already surpasses the total in the first half of 2024.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Sarepta Therapeutics (NasdaqGS:SRPT) Gains 19% Over Past Month Following Japan Approval
Sarepta Therapeutics saw its share price rise by 19% over the past month, a move that notably outpaced the broader market's 1% increase for the week and the 13% gain over the year. This significant increase can be partially attributed to several key announcements, including the FDA's platform technology designation for their rAAVrh74 viral vector, pivotal updates from ongoing studies related to their ELEVIDYS treatment for Duchenne Muscular Dystrophy, and new approval in Japan. These developments highlight the company's continued progress and innovation in gene therapy, reinforcing investor confidence amidst market growth. We've identified 2 weaknesses for Sarepta Therapeutics (1 is a bit concerning) that you should be aware of. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Recent developments for Sarepta Therapeutics have sparked a positive response in short-term share price, primarily driven by advancements in their gene therapy programs. These innovations, particularly the FDA's designation and updates on the ELEVIDYS program, are poised to bolster investor confidence. However, despite this optimism, it's essential to acknowledge that Sarepta's shares have experienced a 37.80% decline over the past three years, highlighting challenges the company has faced. Relative to the biotechnology industry, Sarepta has underperformed in the past year compared to the US Biotechs market, which returned -9.3%. The recent announcements could potentially impact Sarepta's revenue and earnings forecasts considerably. Analysts project a significant annual revenue increase over the next three years, with expectations that profit margins will improve. Crucially, these updates could address operational delays and safety concerns surrounding ELEVIDYS, enhancing the therapy's credibility and market uptake. In terms of valuation, Sarepta's recent share price movements are in the context of an analyst price target of US$89.96, indicating further room for growth if the company's strategic objectives translate into financial success. These factors collectively shape a complex but promising outlook for Sarepta as it navigates both opportunities and challenges in its field. The valuation report we've compiled suggests that Sarepta Therapeutics' current price could be quite moderate. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:SRPT. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
'No recession bet whatsoever': The stock market isn't pricing in any sort of economic downturn, investment firm says
A trend in the stock market shows investors are betting on continued US growth, one firm says. Historically, an increase in defensive valuations has preceded a recession, but that's not happening. Equity managers are acting like "there's no recession risk whatsoever," The Leuthold Group said. Investors are betting that the US economy will continue to grow and they're behaving as if there's "no recession risk whatsoever," market research firm The Leuthold Group wrote in a note last week. That conclusion is based on a key indicator, the S&P 500 Cyclical/Defensive Ratio, which compares the most economically sensitive sectors, like consumer discretionary, industrials, and materials, to more stable areas of the market such as consumer staples, healthcare, and utilities. The Leuthold Group calculates this metric based on price to earnings, price to cash flow, price to sales, and price to book ratios. Cyclical stocks typically trade at a discount during recessions because their earnings are more vulnerable to economic slowdowns. Investors, meanwhile, pay a relative premium for the safety of defensive stocks with more inelastic demand. In May, this ratio hit an all-time high of 1.19, indicating a 19% premium for cyclical stocks relative to defensive shares. This isn't an anomaly, as the ratio has held above 1.05 — placing it in the top 10% of historical readings — for 13 consecutive months. Recession fears have come down since reaching a fever pitch in April. After the announcement of a 90-day tariff pause and trade negotiations with China, the odds of a recession have fallen from 66% to 28% on prediction market Polymarket. However, several Wall Street strategists are still concerned, as a 28% chance of recession is still higher than the long-term average of around 15%. Torsten Sløk, chief economist at Apollo, and Jamie Dimon, CEO of JPMorgan, have been ringing the bell on stagflation concerns. According to The Leuthold Group, a 28% chance of recession is still far too high based on what the market is pricing in. Ahead of past recessions — including 2000, 2008, and 2020 — cyclical sectors were trading at steep discounts to their more stable counterparts. The average valuation gap at pre-recession market peaks was about 25% in favor of defensives. During these recessions, the average valuation gap increased to 38%. "Much of the recession 'discount' in the comparative valuations of Cyclicals occurred during the twelve months (or earlier) preceding the pre-recession stock market peak. Today, that process does not appear to have begun," the firm wrote. The elevated S&P 500 Cyclical/Defensive Ratio also reflects some valuation shifts that have occurred over the last few decades. Defensive stock valuations have been declining as long-term growth for consumer staples and healthcare companies slow down. These companies now trade at a 10% discount to the S&P 500, compared to a medium premium of 10% since 1990. During previous recessionary bear markets, defensives traded at a 33% premium relative to the rest of the market, suggesting room for a defensive comeback if recessionary fears return. If this does occur, investors heavily exposed to cyclicals will suffer the most. Investors are continuing to bet on the most economically sensitive parts of the market. As long as cyclical stocks retain their valuation premium against defensives, it seems like there's no recession scare to be worried about. Read the original article on Business Insider Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Meta in Talks for Scale AI Investment That Could Top $10 Billion
(Bloomberg) -- Meta Platforms Inc. is in talks to make a multibillion-dollar investment into artificial intelligence startup Scale AI, according to people familiar with the matter. Next Stop: Rancho Cucamonga! Where Public Transit Systems Are Bouncing Back Around the World ICE Moves to DNA-Test Families Targeted for Deportation with New Contract Trump Said He Fired the National Portrait Gallery Director. She's Still There. US Housing Agency Vulnerable to Fraud After DOGE Cuts, Documents Warn The financing could exceed $10 billion in value, some of the people said, making it one of the largest private company funding events of all time. The terms of the deal are not finalized and could still change, according to the people, who asked not to be identified discussing private information. Representatives for Scale and Meta declined to comment. Scale AI, whose customers include Microsoft Corp. and OpenAI, provides data labeling services to help companies train machine-learning models and has become a key beneficiary of the generative AI boom. The startup was last valued at about $14 billion in 2024, in a funding round that included backing from Meta and Microsoft. Earlier this year, Bloomberg reported that Scale was in talks for a tender offer that would value it at $25 billion. This would be Meta's biggest ever external AI investment, and a rare move for the company. The social media giant has before now mostly depended on its in-house research, plus a more open development strategy, to make improvements in its AI technology. Meanwhile, Big Tech peers have invested heavily: Microsoft has put more than $13 billion into OpenAI while both Inc. and Alphabet Inc. have put billions into rival Anthropic. Part of those companies' investments have been through credits to use their computing power. Meta doesn't have a cloud business, and it's unclear what format Meta's investment will take. Chief Executive Officer Mark Zuckerberg has made AI Meta's top priority, and said in January that the company would spend as much as $65 billion on related projects this year. The company's push includes an effort to make Llama the industry standard worldwide. Meta's AI chatbot — already available on Facebook, Instagram and WhatsApp — is used by 1 billion people per month. Scale, co-founded in 2016 by CEO Alexandr Wang, has been growing quickly: The startup generated revenue of $870 million last year and expects sales to more than double to $2 billion in 2025, Bloomberg previously reported. Scale plays a key role in making AI data available for companies. Because AI is only as good as the data that goes into it, Scale uses scads of contract workers to tidy up and tag images, text and other data that can then be used for AI training. Scale and Meta share an interest in defense tech. Last week, Meta announced a new partnership with defense contractor Anduril Industries Inc. to develop products for the US military, including an AI-powered helmet with virtual and augmented reality features. Meta has also granted approval for US government agencies and defense contractors to use its AI models. The company is already partnering with Scale on a program called Defense Llama — a version of Meta's Llama large language model intended for military use. Scale has increasingly been working with the US government to develop AI for defense purposes. Earlier this year the startup said it won a contract with the Defense Department to work on AI agent technology. The company called the contract 'a significant milestone in military advancement.' The SEC Pinned Its Hack on a Few Hapless Day Traders. The Full Story Is Far More Troubling Cavs Owner Dan Gilbert Wants to Donate His Billions—and Walk Again Is Elon Musk's Political Capital Spent? What Does Musk-Trump Split Mean for a 'Big, Beautiful Bill'? Cuts to US Aid Imperil the World's Largest HIV Treatment Program ©2025 Bloomberg L.P. Sign in to access your portfolio
